tiprankstipranks
Trending News
More News >
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) AI Stock Analysis

Compare
376 Followers

Top Page

BC

Bicycle Therapeutics

(NASDAQ:BCYC)

Rating:48Neutral
Price Target:
$7.50
▲(0.94%Upside)
Bicycle Therapeutics faces financial challenges with ongoing losses and reliance on external funding, reflected in a low financial performance score. Technical analysis shows bearish trends, further impacting the stock score. While promising corporate events and strong R&D potential provide some positive outlook, the overall risks remain significant.
Positive Factors
Efficacy and Response Rates
The number of confirmed responses increased from 5 to 10 among 20 evaluable patients, demonstrating continued superiority over chemotherapy's 35% overall response rate.
Pipeline Development
The company is planning to disclose additional data and initiate multiple studies, indicating active development and potential future advancements in their pipeline.
Safety Profile
Zelenectide pevedotin continued to show a more favorable safety and tolerability profile vs. Padcev in the combination setting with lower Grade 3+ treatment-related skin reactions.
Negative Factors
Earnings Report
The quarter's earnings report was described as uneventful.
Efficacy Concerns
The efficacy still falls short of the 64-73% overall response rate seen with Padcev, which has increasingly become the standard of care for 1L metastatic urothelial cancer.
Safety Concerns
The safety profile has deteriorated with an increased incidence of peripheral neuropathy.

Bicycle Therapeutics (BCYC) vs. SPDR S&P 500 ETF (SPY)

Bicycle Therapeutics Business Overview & Revenue Model

Company DescriptionBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
How the Company Makes MoneyBicycle Therapeutics generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and royalties on sales of any resulting products. The company also invests in proprietary drug development, aiming to bring its own therapies to market, which could provide significant revenue through direct sales in the future. Additionally, government grants and research funding may contribute to its income, supporting its development activities and innovation in the biopharmaceutical field.

Bicycle Therapeutics Financial Statement Overview

Summary
Bicycle Therapeutics demonstrates strong revenue growth and maintains a robust cash position, crucial for its R&D activities in biotechnology. However, consistent net losses and negative cash flows from operations indicate financial challenges. The company relies on external financing to sustain operations, typical for companies in the biotechnology sector, but it also poses a risk if financing conditions change.
Income Statement
55
Neutral
Bicycle Therapeutics shows strong revenue growth over the years, with Total Revenue increasing from $10.39M in 2020 to $25.73M in TTM. However, the company is still experiencing significant net losses, as reflected in the negative Net Profit Margin and EBIT Margin. The Gross Profit Margin has improved, but the high negative EBIT and EBITDA margins indicate operational inefficiencies.
Balance Sheet
60
Neutral
The balance sheet is supported by a strong cash position, with substantial cash reserves exceeding total debt, resulting in negative net debt. The Debt-to-Equity ratio is low, indicating low leverage. However, the Return on Equity is negative due to ongoing net losses, which is a concern for profitability.
Cash Flow
50
Neutral
The company has a negative Free Cash Flow, but the cash flow from financing activities remains strong, indicating reliance on external funding. The Operating Cash Flow to Net Income ratio is below ideal levels, reflecting operational challenges. However, the company’s ability to raise significant financing is a positive factor.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue25.73M35.27M26.98M14.46M11.70M10.39M
Gross Profit20.17M28.11M20.51M10.78M-33.18M-22.76M
EBITDA-219.83M-164.89M-183.40M-112.96M-64.08M-50.39M
Net Income-203.27M-169.03M-180.66M-112.72M-66.82M-51.01M
Balance Sheet
Total Assets883.89M956.87M595.34M410.61M479.79M161.15M
Cash, Cash Equivalents and Short-Term Investments792.97M879.52M526.42M339.15M438.68M135.99M
Total Debt8.32M9.49M44.96M44.33M44.34M15.78M
Total Liabilities143.56M163.81M224.41M139.83M133.54M65.69M
Stockholders Equity740.33M793.06M370.93M270.78M346.25M95.46M
Cash Flow
Free Cash Flow-182.13M-165.96M-63.56M-105.10M-16.82M-18.99M
Operating Cash Flow-180.23M-164.72M-60.63M-86.11M-14.79M-17.79M
Investing Cash Flow-1.83M-1.24M-2.93M-18.99M-2.03M-1.20M
Financing Cash Flow518.01M519.75M250.03M6.69M320.73M62.84M

Bicycle Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.43
Price Trends
50DMA
8.13
Negative
100DMA
8.83
Negative
200DMA
14.30
Negative
Market Momentum
MACD
-0.29
Positive
RSI
43.95
Neutral
STOCH
48.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCYC, the sentiment is Negative. The current price of 7.43 is below the 20-day moving average (MA) of 7.78, below the 50-day MA of 8.13, and below the 200-day MA of 14.30, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 48.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCYC.

Bicycle Therapeutics Risk Analysis

Bicycle Therapeutics disclosed 74 risk factors in its most recent earnings report. Bicycle Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bicycle Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$603.54M-216.14%203.23%-80.71%
57
Neutral
$626.14M-452.20%8.98%6.32%
52
Neutral
$7.53B0.32-61.76%2.28%16.60%1.56%
48
Neutral
$514.17M-37.13%-38.14%29.69%
47
Neutral
$789.47M-241.16%6.30%29.17%
47
Neutral
$507.33M-41.84%3.95%
OPOPT
40
Underperform
$482.39M
-25.10%-7.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BCYC
Bicycle Therapeutics
7.43
-12.80
-63.27%
QURE
uniQure
14.42
10.64
281.48%
KURA
Kura Oncology
5.86
-14.13
-70.69%
URGN
Urogen Pharma
13.58
-2.52
-15.65%
MGTX
Meiragtx Holdings
7.51
3.42
83.62%
OPT
Opthea Limited Sponsored ADR
3.20
1.24
63.27%

Bicycle Therapeutics Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
Bicycle Therapeutics Approves Proposals at Annual Meeting
Positive
Jun 17, 2025

On June 17, 2025, Bicycle Therapeutics held its annual general meeting where all proposals, including director re-elections and auditor appointments, were approved by shareholders. The meeting saw high shareholder participation, with approximately 98.63% of shares represented, reflecting strong support for the company’s governance and strategic direction.

The most recent analyst rating on (BCYC) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Bicycle Therapeutics Reveals Promising Imaging Data at AACR
Positive
Apr 29, 2025

On April 29, 2025, Bicycle Therapeutics announced additional human radiopharmaceutical imaging data for MT1-MMP at the AACR Annual Meeting 2025, demonstrating the potential of MT1-MMP as a novel cancer target. The data, involving 12 patients with various solid tumors, highlighted the efficacy of Bicycle® Radioconjugates (BRC®) in radiopharmaceutical imaging, showing promising results in tumor targeting and tracer uptake. The company plans to advance its radiopharmaceutical pipeline with initial human imaging data for a second target, EphA2, expected later in 2025, and company-sponsored clinical trials planned for 2026.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 18, 2025